Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Eupraxia Pharmaceuticals ( (TSE:EPRX) ).
Eupraxia Pharmaceuticals has priced a public offering of approximately US$55 million in common shares and pre-funded warrants, with an additional 30-day option for underwriters to buy more shares, and expects the transaction to close on February 20, 2026, pending customary approvals from the Toronto Stock Exchange and Nasdaq. The company plans to deploy the proceeds to advance EP-104GI through preclinical work, Phase 2 and Phase 3 preparations, expand studies into additional gastrointestinal indications such as esophageal strictures and fibrostenotic Crohn’s disease, and fund broader R&D, business development, intellectual property, and corporate infrastructure to support future growth.
The most recent analyst rating on (TSE:EPRX) stock is a Buy with a C$19.00 price target. To see the full list of analyst forecasts on Eupraxia Pharmaceuticals stock, see the TSE:EPRX Stock Forecast page.
Spark’s Take on TSE:EPRX Stock
According to Spark, TipRanks’ AI Analyst, TSE:EPRX is a Neutral.
The score is held back primarily by weak financial performance (pre-revenue, ongoing losses and cash burn), partially offset by a conservatively levered balance sheet. Technicals are the main positive, showing a clear uptrend and constructive momentum, while valuation is constrained by negative earnings and no dividend data.
To see Spark’s full report on TSE:EPRX stock, click here.
More about Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company that leverages its proprietary Diffusphere drug-delivery technology to enable localized, controlled release therapies. The company is focused on addressing significant unmet medical needs, particularly in gastrointestinal disorders, and is advancing a pipeline led by its EP-104GI candidate for Eosinophilic Esophagitis and other GI indications.
Average Trading Volume: 76,530
Technical Sentiment Signal: Buy
Current Market Cap: C$576.6M
For detailed information about EPRX stock, go to TipRanks’ Stock Analysis page.